OriGene Technologies, Inc.
Search:    
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right
 
Home About Us News & Events

spacer

Press Releases and News

divider

Rockville, MD. February 4th, 2016 – OriGene Technologies, Inc., announced today that it has entered into a multi-year antibody development collaboration featuring its proprietary UltraMAB™ technology platform and granted to Dako, an Agilent Technologies company (Santa Clara, CA), a worldwide non-exclusive commercial license to OriGene’s mouse anti-ALK monoclonal antibody clone OTI1A4 for research and diagnostics use within the immunocytochemistry and immunohistochemistry fields.. (Full Press Release)
Rockville, MD – January 7th, 2016 - OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.. (Full Press Release)
ROCKVILLE, MD – Oct 28, 2015 – OriGene Technologies, Inc. (“OriGene”), an industry leader of genome wide products for research and diagnostic applications, announced today that it has acquired Acris Antibodies GmbH (“Acris Antibodies”), a provider of antibodies and other life science related products.. (Full Press Release)

More press release & news >>


Conferences

Where OriGene scientists are presenting their findings and new product launches
divider

AACR Annual Meeting 2016
Apr 16-Apr 20, 2016, New Orleans, LA. Booth #1941

PEGS
Apr 20-Apr 25, 2016, Boston, MA. Booth #141

 

spacer
Inc 5000 Healthcare Company
All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title